SCR7 - Become A Master In 10 Effortless Tasks

Conclusion:?While there was general agreement that oxygen therapy should be used cautiously, there was variation in knowledge of indications for oxygen therapy, use and limitations of monitoring equipment and of delivery devices. The low response rate limits study interpretation; however the response rate raises questions regarding healthcare professionals approach to this commonly used therapy, and may warrant further study. Key words:?oxygen therapy, skills, knowledge, healthcare professionals. YANG J, FULTON F, STANTON J, SWANNEY M Christchurch Hospital, New Zealand Introduction:?Percent predicted DLCO (DLCO%) is SCR7 clinical trial a key value for scoring the hematopoietic cell transplantation-specific co-morbidity index (HCT-CI), a risk assessment tool used prior to hematopoietic stem cell transplantation (HSCT). The HCT-CI was validated using the Dinakara equation for adjusting Mianserin HCl DLCO for haemoglobin (Hb). Our laboratory uses the Cotes Hb adjustment equation as recommended in the ATS/ERS 2005 guidelines. A recent study showed that the Cotes equation decreased DLCO% and increased HCT-CI, predicting higher non-relapse mortality compared to the Dinakara equation. Aim:?Investigate the effect of adjusting DLCO for Hb using two equations on HCT-CI. Method:?Pre-HSCT pulmonary function and clinical Entinostat nmr data in 90 patients from Christchurch, New Zealand were analysed. Hb adjusted DLCO% and HCT-CI were determined using the Cotes and Dinakara equations for each patient. Patients were stratified into low, intermediate or high-risk groups based on HCT-CI scores of 0, 1�C2 or ��?3, respectively. Data were analysed using paired t �C tests. Results:?The mean DLCO% adjusted for Hb was significantly lower using the Cotes equation compared to the Dinakara equation, regardless of Hb levels (Table). The Cotes equation increased HCT-CI in 27 (30%) patients, which promoted 13 (14%) patients from low to intermediate risk and 11 (12%) patients from intermediate to high risk. 3 patients did not change their risk groups. Hb (g/L) Cotes DLCO% Dinakara DLCO% n p value 120 88% 92% 33